In this episode of Better Thinking, Nesh Nikolic speaks with Professor Zoltán Sarnyai about his recent randomized controlled trial on ketogenic metabolic therapy for serious mental illness and the broader implications of this emerging field for the future of psychiatric treatment.Professor Zoltán Sarnyai, Director of the Margaret Roderick Centre for Mental health Research at James Cook University, is a medically trained neuroscientist with an internationally recognised expertise in the neurobiology of stress and mental health disorders. Before moving to Australia, he was University Lecturer in the Department of Pharmacology, University of Cambridge and a Fellow of Pembroke College, where he was Director of Studies for Medicine. He trained at McLean Hospital at Harvard Medical School and at The Rockefeller University, supported by the DuPont-Warren Award and a NARSAD Young Investigator Award, respectively. His group described the role of stress neuropeptides oxytocin and corticotropin-releasing factor in addiction, for which he was awarded the Richter Prize by the International Society of Psychoneuroendocrinology. More recently, he discovered the efficacy of ketogenic metabolic therapy in preclinical models of schizophrenia and is currently conducting the world’s first randomised controlled clinical trial to investigate this in clinical populations. Zoltán was appointed Lady Davis Visiting Professor at Technion-Israel Institute of Technology to study the neuro- metabolic aspects of schizophrenia. Zoltan has published over 150 original research papers, reviews and book chapters, his works have been cited over 10,000 time, with an H index of 50. He is Associate Editor for Nutritional Neuroscience and Frontiers in Neuroscience, and editorial board member of Nutritional Psychiatry and Stress.